Otsuka Pharmaceutical Co., Ltd.

February 22, 2013

L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg
Two New Drug Forms for Carnitine Deficiency To Be Launched on February 26

  • Levocarnitine in two new drug forms, oral solution and injection form, to be launched in addition to existing L-Cartin® tablets; the only treatment in Japan for carnitine deficiency.
  • Oral solution was developed to ease the patients having difficulties taking the carnitine tablets, and the injection form was developed for carnitine-deficient patients who require immediate supplementation of carnitine, or for those unable to orally ingest carnitine.
  • Carnitine deficiency can be found in patients with inborn errors of metabolism and in hemodialysis patients, for example with symptoms such as muscle pains or hypoglycemic coma in severe cases.

Tokyo, Japan, February 22, 2013 - Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) announced today that L-Cartin FF oral solution 10% and L-Cartin FF injection 1000mg, indicated for carnitine deficiency, are to be launched on February 26.